Ozempic’s patent expiry in India on March 20, 2026, has opened the door for generics priced at least 50% lower. Indian pharma giants including Sun Pharma, Dr. Reddy’s, Lupin, Ajanta Pharma, and Mankind Pharma are set to launch versions, fueling demand and reshaping obesity treatment nationwide.
Novo Nordisk’s blockbuster drug Ozempic, based on semaglutide, loses patent protection in India this week. With generics entering the market, obesity treatment costs are expected to halve, making therapies more accessible to millions.
Market Impact
Generics are expected to cost around ₹5,000 per weekly dose, compared to double that for Ozempic. Clinics anticipate a surge in patients seeking affordable weight-loss solutions.
Regulatory Oversight
India’s drug regulator has banned advertising and promotional campaigns for weight-loss programs to prevent aggressive marketing and misuse.
Pharma Players
Sun Pharma, Dr. Reddy’s, Lupin, Ajanta Pharma, and Mankind Pharma are among the companies ready to launch semaglutide generics immediately after expiry.
Key Highlights
• Ozempic patent expires in India on March 20, 2026
• Generics expected to be 50% cheaper, around ₹5,000 per weekly dose
• At least five Indian pharma firms ready to launch versions
• Clinics expect obesity patient numbers to double
• Regulator bans weight-loss drug advertising to curb misuse
Sources: Bloomberg, Business Standard, Hindustan Times